Abstract
Biological markers are an important element in the algorithms for diagnosis, risk stratification and prognosis in patients with heart failure. Recognized markers – natriuretic peptides – has a number of limitations, and in recent years many new substances have appeared – which are considered as candidates for biomarkers of heart failure. One of the most promising biomarkers of “mechanical” myocardial stress is soluble ST2, and this review discussing the possibility of using ST2 in clinical practice in patients with ischemic heart failure. This review and clinical case is devoted to discussing the possibility of using soluble ST2 as a biomarker of heart failure for the purpose of diagnosis, assessing the prospects for revascularization, stratifying the risk of negative events, assessing the prognosis and effectiveness of treatment in patients with LV ischemic dysfunction.
References
- Groenewegen A., Rutten F.H., Mosterd A., Hoes A.W. Epidemiology of heart failure. Eur. J. Heart Fail. 2020; 22: 1342–56. DOI: 10.1002/ejhf.1858
- Pyka Ł., Hawranek M., Gąsior M. Revascularization in ischemic heart failure with reduced left ventricular ejection fraction. The impact of complete revascularization. Kardiochir. Torakochir. Pol. 2017; 14 (1): 37–42. DOI: 10.5114/kitp.2017.66928
- Neumann F.J., Sousa-Uva M., Ahlsson A., Alfonso F., Banning A., Benedetto U. et al. 2018 ESC/EACTS Guidelines on myocardial revascularization [published correction appears in Eur. Heart J. 2019; 40 (37): 3096]. Eur. Heart J. 2019; 40 (2): 87–165. DOI: 10.1093/eurheartj/ehy394
- Sanada S., Hakuno D., Higgins L.J., Schreiter E.R., McKenzie A., Lee R.T. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J. Clin. Invest. 2007; 117: 1538–49. DOI: 10.1172/JCI30634
- Weinberg E.O., Shimpo M., Hurwitz S., Tominaga S., Rouleau J.L., Lee R.T. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation. 2003; 107: 721–6. DOI: 10.5935/abc.20150151
- Rahimtoola S.H., La Canna G., Ferrari R. Hibernating myocardium: another piece of the puzzle falls into place. J. Am. Coll. Cardiol. 2006; 47 (5): 978–80. DOI: 10.1016/j.jacc.2005.11.038
- Abraham A., Nichol G., Williams KA., Guo A., Kemp R. et al. 18F-FDG PET imaging of myocardial viability in an experienced center with access to 18F-FDG and integration with clinical management teams: the OttawaFIVE substudy of the PARR 2 trial. J. Nucl. Med. 2010; 51 (4): 567–74. DOI: 10.2967/jnumed.109.065938
- Cleland J.G., Calvert M., Freemantle N., Arrow Y., Ball S.G., Bonser R.S. et al. The Heart Failure Revascularisation Trial (HEART). Eur. J. Heart Fail. 2011; 13 (2): 227–33. DOI: 10.1093/eurjhf/hfq230
- Watanabe H., Shiomi H., Morimoto T., Furukawa Y., Nakagawa Y., Ando K. et al. Percutaneous coronary intervention versus coronary arterial bypass grafting in patients with multi-vessel coronary revascularization (from the CREDO-Kyoto PCI/CABG registry/cohort-2). Catheter. Cardiovasc. Interv. 2020; 96 (1): 42–51. DOI: 10.1002/ccd.28420
- Hassanabad A.F., MacQueen K.T., Ali I. Surgical Treatment for Ischemic Heart Failure (STICH) trial: A review of outcomes. J. Card. Surg. 2019; 34 (10): 1075–82. DOI: 10.1111/jocs.14166
- Wrobel K., Stevens S.R., Jones R.H., Selzman C.H., Lamy A., Beaver T.M. et al. Influence of baseline characteristics, operative conduct, and postoperative course on 30-day outcomes of coronary artery bypass grafting among patients with left ventricular dysfunction: Results from the Surgical Treatment for Ischemic Heart Failure (STICH) Trial. Circulation. 2015; 132 (8): 720–30. DOI: 10.1161/CIRCULATIONAHA.114.014932
- Bouabdallaoui N., Stevens S.R., Doenst T., Petrie M.C., Al-Attar N., Ali I.S. et al. Society of Thoracic Surgeons Risk Score and EuroSCORE-2 appropriately assess 30-day postoperative mortality in the STICH trial and a contemporary cohort of patients with left ventricular dysfunction undergoing surgical revascularization. Circ. Heart Fail. 2018; 11 (11): e005531. DOI: 10.1161/CIRCHEARTFAILURE.118.005531
- Matskeplishvili S.T., Buziashvili Yu.I., Ioshina V.I., Asymbekova E.U., Golubev E.P. Studies on reversible forms of myocardial dysfunction is the main target for surgery. In: Chronic heart failure in patients with coronary heart disease: strategic approaches to making the optimal clinical decision. Moscow; 2015: 289–92 (in Russ.).
- Yancy C.W., Jessup M., Bozkurt B., Butler J., Casey D.E. Jr., Drazner M.H. et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 2013; 62 (16): 147–239. DOI: 10.1016/j.jacc.2013.05.019
- Bonow R.O., Panza J.A., Ellis A.M., Al-Khalidi H.R., Holly T.A., Berman D.S. et al. Myocardial viability and long-term outcomes in ischemic cardiomyopathy. N. Engl. J. Med. 2019; 381 (8): 739–48. DOI: 10.1056/NEJMoa1807365
- Kristensen S.L. Individualizing surgical revascularization in patients with ischaemic heart failure – a further dive into STICHES. Eur. J. Heart Fail. 2019; 21 (3): 382–4. DOI: 10.1002/ejhf.1426
- Windecker S., Kolh P., Alfonso F., Collet G., Cremer J., Falk V. et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for CardioThoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur. Heart J. 2014; 35 (37): 2541–619. DOI: 10.1093/eurheartj/ehu278
- Hote M. Cardiac surgery risk scoring systems: In quest for the best. Heart Asia. 2018; 10 (1): e011017. DOI: 10.1136/heartasia-2018-011017
- Guillet L., Moury P.H., Bedague D., Durand M., Martin C., Payen J.F. et al. Comparison of the additive, logistic European system for cardiac operative risk (EuroSCORE) with the EuroSCORE 2 to predict mortality in high-risk cardiac surgery. Ann. Card. Anaesth. 2020; 23 (3): 277–82. DOI: 10.4103/aca.ACA_209_18
- Subramani S. The current status of EuroSCORE II in predicting operative mortality following cardiac surgery. Ann. Card. Anaesth. 2020; 23 (3): 256–7. DOI: 10.4103/aca.ACA_32_19
- Ramkumar N., Jacobs J.P., Berman R.B., Parker D.M., MacKenzie T.A., Likosky D.S. et al. Cardiac biomarkers predict long-term survival after cardiac surgery. Ann. Thorac. Surg. 2019; 108 (6): 1776–82. DOI: 10.1016/j.athoracsur.2019.04.123
- Polineni S., Parker D.M., Alam S.S., Thiessen-Philbrook H., McArthur E., DiScipio A.W. et al. Predictive ability of novel cardiac biomarkers ST2, galectin-3, and NT-ProBNP before cardiac surgery. J. Am. Heart Assoc. 2018; 7 (14): e008371. DOI: 10.1161/JAHA.117.008371
- Holm J., Vidlund M., Vanky F., Friberg Ö., Ha°kanson E., Walther S., Svedjeholm R. EuroSCORE II and N-terminal pro-B-type natriuretic peptide for risk evaluation: an observational longitudinal study in patients undergoing coronary artery bypass graft surgery. Br. J. Anaesth. 2014; 113 (1): 75–82. DOI: 10.1093/bja/aeu088
- Suc G., Estagnasie P., Brusset A., Procopi N., Squara P., Nguyen L.S. Effect of BNP on risk assessment in cardiac surgery patients, in addition to EuroScore II. Sci. Rep. 2020; 10 (1): 10865. DOI: 10.1038/s41598-020-67607-0
- Preeshagul I., Gharbaran R., Jeong K.H., AbdelRazek A., Lee L.Y., Elman E., Suh K.S. Potential biomarkers for predicting outcomes in CABG cardiothoracic surgeries. J. Cardiothorac. Surg. 2013; 8: 176. DOI: 10.1186/1749-8090-8-176
- Kopec M., Duma A., Helwani M.A., Brown J., Brown F., Gage B.F. et al. Improving prediction of postoperative myocardial infarction with high-sensitivity cardiac troponin T and NT-proBNP. Anesth. Analg. 2017; 124 (2): 398–405. DOI: 10.1213/ANE.0000000000001736
- Liu H., Wang C., Liu L., Zhuang Y., Yang X., Zhang Y. Perioperative application of N-terminal pro-brain natriuretic peptide in patients undergoing cardiac surgery. J. Cardiothorac. Surg. 2013; 8: 1. DOI: 10.1186/1749- 8090-8-1
- Khan M.S., Yamashita K., Sharma V., Ranjan R., Selzman C.H., Dosdall D.J. Perioperative biomarkers predicting postoperative atrial fibrillation risk after coronary artery bypass grafting: A narrative review. J. Cardiothorac. Vasc. Anesth. 2020; 34 (7): 1933–41. DOI: 10.1053/j.jvca.2019.09.022
- Wang B., Cheng Z., Ge Z., Peng B., Zhao Z., Quan X. Level of perioperative B-type natriuretic peptide associates with heart function after on-pump coronary artery bypass graft surgery on a beating heart. Pak. J. Med. Sci. 2015; 31 (2): 379–82. DOI: 10.12669/pjms.312.6189
- Redfors B., Chen S., Crowley A., Ben-Yehuda O., Gersh B.J., Lembo N.J. et al. B-type natriuretic peptide assessment in patients undergoing revascularization for left main coronary artery disease: Analysis from the EXCEL trial. Circulation. 2018; 138 (5): 469–78. DOI: 10.1161/CIRCULATIONAHA.118.033631
- Kamardinov D.K., Songurov R.N., Ioshina V.I., Buziashvili Yu.I. Soluble ST2 – as a biomarker, a tool for risk stratification and therapeutic target in patients with chronic heart failure. Kardiologiia. 2020; 60 (2): 111–21 (in Russ.). DOI: 10.18087/cardio.2020.2.n816
- Ahmad T., Fiuzat M., Neely B., Neely L.M., Pencina M.J., Kraus W.E. et al. Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure. JACC Heart Fail. 2014; 2 (3): 260–8. DOI: 10.1016/j.jchf.2013.12.004
- Malhotra A.K., Ramakrishna H. N-terminal pro B type natriuretic peptide in high cardiovascular-risk patients for noncardiac surgery: What is the current prognostic evidence? Ann. Card. Anaesth. 2016; 19 (2): 314–20. DOI: 10.4103/0971-9784.179636
About the authors
- Rashid N. Songurov, Cardiologist; ORCID
- Inna V. Koksheneva, Dr. Med. Sci., Senior Researcher; ORCID
- Rustam M. Ibragimov, Cand. Med. Sci., Researcher; ORCID
- Viktor P. Alimov, Cardiologist; ORCID
- El’vina F. Tugeeva, Dr. Med. Sci., Senior Researcher; ORCID
- Yuriy I. Buziashvili, Dr. Med. Sci., Professor, Academician of RAS, Head of Department; ORCID
